Determining the effectiveness of Sambucol in reducing the duration and symptoms of the common cold in children and teens

Pharmacare Pty Ltd0 个研究点目标入组 198 人开始时间: 2023年3月17日最近更新: 2024年4月15日

试验速览

暂无简介。

•1.Willingness to not take any other over-the-counter cold medication for the duration of the study
•2.Children that are generally healthy
•3.Commenced cold within in the last 3 days (72 hours)
•4.Have at least one of the following symptoms: stuffy or runny nose or discolored nasal secretions, sneezing; scratchy or sore throat; cough; or hoarseness of voice.
•5.Parent / legal guardian has provided informed consent.

•Children and adolescents who meet the following exclusion criteria will not be included in the trial:
•1.Significant acute illness (including a previous common cold) within the 2 weeks prior to commencement including allergic rhinitis; or an active systemic infection or medical condition that might require treatment or therapeutic intervention during the study
•2.History of severe allergic or idiosyncratic reaction reactions or anaphylaxis to any medication; and known allergy to elderberry or excipients of the investigational product
•3.Currently on regular treatment with antibiotics, corticosteroids, antihistamines, antivirals, non-steroidal anti-inflammatory drugs, anticancer drugs, or immune suppressants.
•4.Use of antibiotics within 4 weeks before commencement.
•5.Use of any other complementary medicine (herbal or vitamin or mineral supplements) during the trial.
•6.Influenza vaccination within 3 months before commencement.
•7.Living in a home exposed to passive smoking.
•8.Known asthma, chronic disease (e.g., diabetes, cystic fibrosis, arthritis, genetic condition or severe eczema) or immunodeficiency disorder (e.g., Childhood leukemia).

发起方

Pharmacare Pty Ltd